CD10 is a critical antigen for the distinction of folliclecenter lymphoma from other B-cell lymphomas composed of small cells in fine-needle aspiration specimens, tissue core biopsies, and bone marrow. In addition, CD10 is expressed in a subset of diffuse large B-cell lymphomas (DLBCLs), where it may be an adverse prognostic indicator. We have previously demonstrated that CD10 expression detected by multiparameter flow cytometry (FC) with cluster analysis is highly sensitive and specific for follicle-center lymphoma in the differential diagnosis of small B-cell lymphomas. In this study, we assessed the utility of paraffin section immunohistochemistry (IHC) for CD10 compared with FC in a cohort of 50 DLBCLs. IHC for CD10 was technically successful in 47 of the 50 (94%) DLBCLs; 3 failed based on lack of internal CD10 reactivity. CD10 was expressed by FC in 20 of 47 DLBCLs (43%); CD10 was positive by IHC in 15 of these (75%). All 27 cases that were CD10(؊) by FC were negative by IHC. The level of CD10 expression by FC in the 5 FC(؉)/IHC(؊) cases ranged from relatively dim to bright. Our results indicate 75% sensitivity and 100% specificity of CD10 expression by IHC compared with multiparameter FC with cluster analysis and a 6% technical failure rate.
though CD10 is not lineage specific, it is a useful marker in the differential diagnosis of B-cell lymphomas, because it is expressed on the vast majority of follicle-center lymphomas and Burkitt lymphomas and in a subset of diffuse large B-cell lymphomas (DLBCL; 5). The function of CD10 in the B-cell lymphomas is not well defined. We and others have recently identified that CD10 expression on DLBCL may be associated with an unfavorable clinical course (6, 7) .
CD10 can be reliably detected by multiparameter flow cytometry (FC) with cluster analysis with a sensitivity of 98% and specificity of 95% for the differential diagnosis of low-grade follicle-center lymphoma from other small B-cell lymphomas (8) . Recently, paraffin-reactive antibodies for CD10 have become commercially available (9) . Immunohistochemistry (IHC) for CD10 is a practical method that is of particular value in retrospective studies of CD10 expression in paraffin-embedded tissue. However, the performance characteristics of paraffin-reactive CD10 antibodies in non-Hodgkin's lymphoma have not been extensively studied. The present study was designed to compare IHC with FC in the detection of CD10 in a cohort of DLBCLs.
MATERIALS AND METHODS

Case Selection
Fifty consecutive cases of DLBCL with available histologic sections and paraffin-embedded tissue blocks were retrieved from the clinical flow cytometry database at the University of Texas Southwestern Medical Center from April 1994 to July 1999.
Flow Cytometry
Fresh biopsy tissue was sliced and disaggregated through a Ͻ100-m mesh, and cells were suspended in 5% newborn calf serum in RPMI 1640 tissue culture medium (Life Technology, Rockville, MD). Cell counts were performed manually, and 500,000 cells per tube were washed with a solution of phosphate buffered saline (PBS), 0.0455% sodium azide, and 0.1% bovine serum albumin and then incubated with either a three-color or four-color combination of antibodies. Antibodies against CD2(55.2), CD3(SK7), CD4(SK3), CD5(L17F12), CD7(4H9), CD8(SK1), CD10(W8E7), CD19(SJ25C1), CD20(L27), CD38(HB7), CD45(2D1), CD45RO(UCHL-1), and monoclonal (TB28 -2) and (I-155-2) immunoglobulins were obtained from Becton Dickinson (San Jose, CA). Antibodies against FMC7(FMC7), CD23(B6), and polyclonal immunoglobulin kappa (goat) and lambda (goat) were obtained from Coulter-Immunotech (Hialeah, FL). Anti-CD30(BerH2) was obtained from DAKO (Carpinteria, CA). These antibodies were conjugated with fluorescein isothiocyanate (FITC), phycoerythrin, peridinin chlorophyll protein, or allophycocyanin. CD10 expression was determined using one of the following antibody combinations: CD10-FITC-CD38-phycoerythrin-CD20-peridinin chlorophyll protein or CD10-FITC-CD19-phycoerythrin-CD20-peridinin chlorophyll protein-CD38-allophycocyanin. Twenty microliters of CD10 antibody was used; this amount was determined by previous titration studies. Specimens were incubated at 2-8°C in the dark for 20 minutes; washed with a solution of PBS, 0.0455% sodium azide, and 0.1% bovine serum albumin; and resuspended in 1% paraformaldehyde in PBS. Flow-cytometric data were acquired using three-color FACScan or four-color FACSCalibur flow cytometry instruments with CELLQuest software (Becton Dickinson). Data analysis was performed using Paint-a-Gate software (Becton Dickinson). Nonviable cells and debris were excluded based on forward and orthogonal light scatter properties. Antigen expression was assessed as an overt qualitative shift of the tumor cell population relative to the same population identified by scatter characteristics in an isotypic control tube. In equivocal cases, positivity was defined as 10% of lymphoma events beyond a 2% threshold, based on the same population in an isotypic control tube. Granulocytes were used as an internal CD10-positive control.
Histology and Immunohistochemistry
Initial diagnostic biopsies were fixed in B5 fixative and/or 10% neutral buffered formalin, embedded in paraffin, and sectioned at 3 m. Sections were stained with hematoxylin and eosin for morphologic evaluation.
Immunohistochemistry was performed on the paraffin sections (29 B5 fixed and 21 formalin fixed) with monoclonal anti-CD10 (56C6, Vector, Burlingame, CA) using a TechMate automated immunostainer (Ventana Biotek, Tucson, AZ) and a streptavidin-biotin peroxidase detection system. For antigen retrieval, sections were placed in 200-mL of Antigen Retrieval Citrate buffer (BioGenex, San Ramon, CA), pH 6.8, and boiled for 5 minutes. After adding 50 mL of deionized water, the buffer was again brought to a boil for 5 minutes. The slides were allowed to cool in buffer for 20 minutes before further processing. CD10 expression by IHC was evaluated without knowledge of the results of flowcytometric CD10 phenotype. IHC was considered to be successful if internal control cells (granulocytes, fibroblasts, or myoepithelial cells) exhibited CD10 reactivity. Cases were scored as positive if Ͼ5% of the lymphoma cells exhibited cytoplasmic or membrane staining.
RESULTS
CD10 Expression by FC
All cases consisted of a population of neoplastic large B cells with restricted immunoglobulin light chain expression or lack of surface light chains by three-or four-color flow cytometry. Analysis of CD10 expression by FC is illustrated in Figure 1 . Of the 50 cases, 22 (44%) were CD10(ϩ), and 28 (56%), CD10(Ϫ). Large lymphoma cells often showed higher background staining than did small lymphocytes. This effect is largely caused by cellular autofluorescence (data not shown). Some DLBCLs with a CD10 fluorescence shift of the tumor population relative to nonneoplastic B lymphocytes were seen to be CD10(Ϫ) when compared with the tumor population in the isotypic control tube (Fig. 2) .
CD10 Expression by IHC
Forty-seven of fifty cases (94%) were successfully evaluated by IHC; three cases failed IHC based on lack of internal CD10 reactivity in granulocytes or other cells (1 fixed in B5 and 2 fixed in formalin; Fig.  3 ). Fifteen cases (32%) were CD10(ϩ), and 32 (68%), CD10(Ϫ). The CD10-staining pattern appeared to be mainly cytoplasmic and varied from patchy to diffuse (Fig. 3) . At least 10% of tumor cells exhibited reactivity in all CD10(ϩ) cases. All CD10(Ϫ) cases showed no positive staining in any tumor cells, but reactivity was observed in internal control cells such as granulocytes, fibroblasts, and myoepithelial cells (Fig. 3) .
Comparison of CD10 Expression by FC and IHC
The results of IHC and FC are compared in Table 1 . Five of 49 cases (11%) showed discordance between CD10 expression by FC and IHC; all 5 were IHC(Ϫ)/FC(ϩ). CD10 was positive by IHC in 15 of the 20 FC-positive cases (75% sensitivity compared with FC). All 27 cases that were CD10(Ϫ) by IHC were negative by FC (100% specificity com-pared with FC). The five IHC(Ϫ)/FC(ϩ) cases showed variable CD10 levels by FC, ranging from relatively dim to bright (Fig. 4) ; three of these cases were B5 fixed, and two were formalin fixed.
DISCUSSION
CD10 is a key molecule in the classification of B-lineage lymphomas and characterization of acute leukemias (3, 5, 10) . Reliable detection of CD10 expression is of great value in diagnosis and prognostic assessment in hematolymphoid neoplasms. In the past, anti-CD10 antibodies were useful only in frozen-section immunophenotyping and flow cytometry; they lacked reactivity in fixed paraffinembedded tissue (3) . Recently, CD10 immunostaining in paraffin-embedded tissue has been achieved with a newly generated monoclonal antibody (56C6; 9), which has been proven to be reactive with various cell types including renal tubules, glomeruli, brush borders of the intestine, hepatic canaliculi, syncytiotrophoblasts, and lymphoid germinal centers (9) . MAb 56C6 has also been shown to be immunoreactive with a variety of neoplasms such as renal cell carcinoma, transitional cell carcinoma, prostatic adenocarcinoma, endometrial stromal sarcoma, rhabdomyosarcoma, pancreatic adenocarcinoma, schwannoma, and malignant melanoma (11) . In addition, the antibody is effective in detection of CD10 on a range of hematolymphoid neoplasms (12-16), but its utility in lymphomas has not been extensively studied.
CD10 is expressed in a subset of DLBCL, a heterogeneous group of non-Hodgkin's lymphomas (6, 7, 17, 18) . The majority of DLBCL patients can be cured with current treatment regimens, whereas a minority fail to achieve complete remission and rapidly progress to death. Therefore, studies have been undertaken to identify markers to dissect DL-BCL into distinct biologic categories. CD10 expression in DLBCL has been shown to correlate with bcl-2 gene rearrangement in a single study (17) ; however, bcl-2 protein expression rather than bcl-2 translocation affects patient survival (19 -22) . We have recently demonstrated that CD10(ϩ) de novo DLBCL is associated with a significantly lower rate of complete remission, whereas CD10(ϩ) and CD10(Ϫ) DLBCLs are similar with regard to a variety of other clinical and pathologic features (6) . Furthermore, we demonstrated that patients with dual CD10(ϩ)/bcl-2(ϩ) tumors showed a markedly worse complete remission rate and overall survival (6) . Similarly, Uherova et al. (7) reported that CD10 expression in DLBCL correlated with shortened overall survival. In contrast, Harada et al. (18) found no difference in overall survival between CD10(ϩ) and CD10(Ϫ) DLBCL patients. The availability of paraffin-reactive antibodies directed against CD10 suggests that retrospective studies with fixed tissue may be possible to confirm the prognostic significance of CD10 on DLBCL.
In the present study, we demonstrated that IHC with MAb 56C6 is 100% specific for CD10 detection in a series of DLBCL compared with multiparameter FC. However, IHC is only 75% sensitive for CD10 compared with FC. A potential explanation for this difference is a lower detection threshold of FC compared with IHC, whereby dim antigen expression may be easily distinguished from background. However, the broad range of CD10 expression by FC in the IHC(Ϫ) cases in the current study does not support this hypothesis. Alternatively, CD10 epitope recognition by MAb 56C6 may be less stable in lymphoma cells than in other cell types in fixed tissue. IHC worked well in our laboratory based on CD10 reactivity in internal tissue controls, with a 94% technical success rate. The failures in CD10 IHC are most likely related to fixation issues. However, data regarding time and length of fixation in these cases are not available because of the retrospective nature of this study. It is well known that differences in fixation and antigen retrieval may have a large impact on the performance of IHC stains. For example, overfixation in B5 may result in nonspecific staining (23) .
A few studies have addressed the utility of paraffin-section IHC for the detection of CD10. Kurtin et al. (14) demonstrated that IHC agreed with FC-frozen-section immunoperoxidase satin (FSIP) in 80% of low-grade follicle-center lymphomas. In their series, 92% of follicle-center lymphomas expressed CD10 by IHC. Among the 20 cases with available FC-FSIP results for comparison, 18 were CD10(ϩ) by IHC, and 16 were CD10(ϩ) by FC-FSIP. It is possible that IHC is more sensitive for CD10 detection in low-grade FCL than is DLBCL.
A high correlation of CD10 detection between IHC and FC (98%) in acute leukemia was reported by Bavikatty et al. (12) . The high density of CD10 antigen on most precursor B-cell acute lymphoblastic leukemias may enhance the antigen detection by IHC. On the other hand, there may be some cell type-related variability of antigen recognition. For example, CD10 epitopes on large lymphoma cells may be less stable and retrievable. Different molecular forms of CD10 cDNAs and proteins are found in different cell types (24 -28) . However, the stability of CD10 protein in different cell types has not been investigated. Finally, the discrepancies of CD10 IHC sensitivity between our results and others may represent greater sensitivity of our three-or An additional practical point illustrated in this study is the observation that large lymphoma cells often have higher nonspecific fluorescence than do small cells by FC, producing a potential pitfall in interpretation. This phenomenon appears to be largely due to cellular autofluorescence. Therefore, comparison of fluorescence intensity with an internal negative population is insufficient for immunophenotypic characterization of large B-cell lymphomas. Careful comparison of CD10 expression on large cells with the same population in an isotypic control tube is necessary for accurate interpretation. We have also encountered this phenomenon in other neoplastic processes composed of large cells (e.g., acute myeloid leukemia, anaplastic largecell lymphoma).
In conclusion, we demonstrated that CD10 IHC is highly specific for CD10 detection in DLBCL compared with FC, but it is less sensitive. These findings have implications for the use of CD10 IHC in the identification of large B-cell lymphomas of follicular origin.
